
1. lancet infect dis. 2017 feb;17(2):164-173. doi: 10.1016/s1473-3099(16)30409-1.
epub 2016 nov 3.

genetic markers associated dihydroartemisinin-piperaquine failure in
plasmodium falciparum malaria cambodia: genotype-phenotype association
study.

amato r(1), lim p(2), miotto o(3), amaratunga c(4), dek d(5), pearson rd(6),
almagro-garcia j(6), neal at(4), sreng s(5), suon s(5), drury e(7), jyothi d(7), 
stalker j(7), kwiatkowski dp(6), fairhurst rm(8).

author information: 
(1)wellcome trust sanger institute, hinxton, uk; centre genomics global
health, wellcome trust centre human genetics, oxford, uk. electronic address:
ra4@sanger.ac.uk.
(2)national institute allergy infectious diseases, national institutes 
health, rockville, md, usa; national center parasitology, entomology, and
malaria control, phnom penh, cambodia.
(3)wellcome trust sanger institute, hinxton, uk; centre genomics global
health, wellcome trust centre human genetics, oxford, uk; mahidol-oxford
tropical medicine research unit, mahidol university, bangkok, thailand.
(4)national institute allergy infectious diseases, national institutes 
health, rockville, md, usa.
(5)national center parasitology, entomology, malaria control, phnom penh,
cambodia.
(6)wellcome trust sanger institute, hinxton, uk; centre genomics global
health, wellcome trust centre human genetics, oxford, uk.
(7)wellcome trust sanger institute, hinxton, uk.
(8)national institute allergy infectious diseases, national institutes 
health, rockville, md, usa. electronic address: rfairhurst@niaid.nih.gov.

comment in
    lancet infect dis. 2017 feb;17(2):119-121.

background: prevalence artemisinin-resistant plasmodium falciparum
malaria increases greater mekong subregion, emerging resistance partner
drugs artemisinin combination therapies seriously threatens global efforts 
treat eliminate disease. molecular markers predict failure of
artemisinin combination therapy urgently needed monitor spread of
partner drug resistance, recommend alternative treatments southeast
asia beyond.
methods: genome-wide association study 297 p falciparum isolates from
cambodia investigate relationship 11 630 exonic single-nucleotide
polymorphisms (snps) 43 copy number variations (cnvs) in-vitro
piperaquine 50% inhibitory concentrations (ic50s), tested whether these
genetic variants markers treatment failure with
dihydroartemisinin-piperaquine. survival analysis 133 patients
to determine whether candidate molecular markers predicted parasite recrudescence
following dihydroartemisinin-piperaquine treatment.
findings: piperaquine ic50s increased significantly 2011 2013 three
cambodian provinces (2011 vs 2013 median ic50s: 20·0 nmol/l [iqr 13·7-29·0] vs
39·2 nmol/l [32·8-48·1] ratanakiri, 19·3 nmol/l [15·1-26·2] vs 66·2 nmol/l
[49·9-83·0] preah vihear, 19·6 nmol/l [11·9-33·9] vs 81·1 nmol/l
[61·3-113·1] pursat; p≤10-3; kruskal-wallis test). genome-wide analysis
of snps identified chromosome 13 region associates raised piperaquine
ic50s. non-synonymous snp (encoding glu415gly substitution) region,
within gene encoding exonuclease, associates parasite recrudescence
following dihydroartemisinin-piperaquine treatment. genome-wide analysis cnvs 
revealed single copy mdr1 gene chromosome 5 novel
amplification plasmepsin 2 plasmepsin 3 genes chromosome 14 also
associate raised piperaquine ic50s. adjusting covariates, both
exo-e415g plasmepsin 2-3 markers significantly associate (p=3·0 × 10-8 and
p=1·7 × 10-7, respectively) decreased treatment efficacy (survival rates
0·38 [95% ci 0·25-0·51] 0·41 [0·28-0·53], respectively).
interpretation: exo-e415g snp plasmepsin 2-3 amplification markers of
piperaquine resistance dihydroartemisinin-piperaquine failures cambodia,
and help monitor spread phenotypes countries the
greater mekong subregion, elucidate mechanism piperaquine resistance. 
since plasmepsins involved parasite's haemoglobin-to-haemozoin
conversion pathway, targeted related antimalarials, plasmepsin 2-3
amplification probably mediates piperaquine resistance.
funding: intramural research program us national institute allergy 
infectious diseases, national institutes health, wellcome trust, bill &
melinda gates foundation, medical research council, uk department for
international development.

copyright © 2017 author(s). published elsevier ltd. open access
article cc license. published elsevier ltd.. rights reserved.

doi: 10.1016/s1473-3099(16)30409-1 
pmcid: pmc5564489
pmid: 27818095  [indexed medline]

